Clinical Trial Update: Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vemurafenib with cobimetinib (continuous and intermittent) in BRAFV600-mutant unresectable/metastatic melanoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Grupo Español Multidisciplinar de Melanoma | Conditions: Melanoma | Phase 2 | Status: COMPLETED